Physician profile
Jeffrey Wayne Smith
NPI 1376636969
$381.85
in general payments reported to CMS, 2019-2025
14 companies · none reported in 2025
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $95.51 · 2020: $28.33 · 2021: $99.62 · 2022: $90.47 · 2023: $3.08 · 2024: $64.84.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $64.84 · Education: $3.08.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $64.84 |
| Education | $3.08 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Amgen INC. | $69.35 | 2021-2022 | |
| Novo Nordisk INC | $57.41 | 2021-2024 | Wegovy |
| Beckman Coulter, INC. | $43.65 | 2022 | |
| Astrazeneca Pharmaceuticals Lp | $35.13 | 2019 | |
| Otsuka America Pharmaceutical, INC. | $31.08 | 2020-2021 | |
| Fresenius USA Marketing, INC. | $27.54 | 2019-2024 | |
| Bayer Healthcare Pharmaceuticals INC. | $24.41 | 2024 | |
| Opko Pharmaceuticals, LLC | $18.75 | 2019 | |
| Novartis Pharmaceuticals Corporation | $15.19 | 2019 | |
| Vifor Pharma, INC. | $14.90 | 2022 | |
| Abbott Laboratories | $14.74 | 2022 | |
| Alexion Pharmaceuticals, INC. | $14.42 | 2019 | |
| Mallinckrodt Hospital Products INC. | $12.20 | 2020 | |
| Travere Therapeutics, INC. | $3.08 | 2023 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Jeffrey Smith listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.